Nanosonics Ltd (ASX: NAN) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Nanosonics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$1.48 billion
P/E Ratio
144.93
Dividend Yield
0.00%
Shares Outstanding
302.32 million
Earnings per share
0.034
Dividend per share
N/A
Year To Date Return
12.82%
Earnings Yield
0.69%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Nanosonics Ltd (ASX: NAN)
Latest News
Share Market News
Here are the top 10 ASX 200 shares today
Opinions
3 ASX small-cap shares I think could become the blue chips of the future
How to invest
$20k invested in these ASX 200 shares 10 years ago is now worth how much?
Share Market News
6 ASX shares that short sellers are racing to close their positions on
Share Fallers
Why ARB, Magellan, Nanosonics, and St Barbara shares are dropping today
Share Market News
5 things to watch on the ASX 200 on Wednesday
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Share Fallers
Why ANZ, Elders, Nanosonics, and Pointsbet shares are falling today
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Broker Notes
3 ASX 200 stocks brokers just upgraded to ‘buy’
Frequently Asked Questions
-
No, Nanosonics Ltd does not pay dividends at this stage.
-
Nanosonics Ltd listed on the ASX on 17 May 2007.
NAN ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Nanosonics Ltd
Nanosonics Ltd (ASX: NAN) is an Australian healthcare company specialising in infection prevention.
The company has developed and commercialised an automated disinfection technology, the trophon device. Nanosonics says it represents the first major innovation in high-level disinfection for ultrasound probes in more than two decades and is fast becoming the global standard of care for ultrasound probe disinfection. The company also manufactures and distributes other related technologies.
Nanosonics is based in Sydney with sales offices in the US and Europe.
NAN Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 10 Aug 2023 | $4.88 | $0.04 | 0.83% | 806,929 | $4.81 | $4.92 | $4.80 |
| 09 Aug 2023 | $4.84 | $0.18 | 3.86% | 962,008 | $4.65 | $4.90 | $4.65 |
| 08 Aug 2023 | $4.66 | $0.03 | 0.65% | 662,047 | $4.60 | $4.70 | $4.59 |
| 07 Aug 2023 | $4.63 | $-0.16 | -3.34% | 515,970 | $4.75 | $4.76 | $4.56 |
| 04 Aug 2023 | $4.79 | $0.11 | 2.35% | 602,965 | $4.60 | $4.80 | $4.60 |
| 03 Aug 2023 | $4.68 | $0.03 | 0.65% | 819,993 | $4.56 | $4.68 | $4.51 |
| 02 Aug 2023 | $4.65 | $-0.13 | -2.72% | 650,343 | $4.71 | $4.75 | $4.64 |
| 01 Aug 2023 | $4.78 | $0.05 | 1.06% | 194,425 | $4.72 | $4.80 | $4.71 |
| 31 Jul 2023 | $4.73 | $-0.01 | -0.21% | 614,198 | $4.77 | $4.83 | $4.70 |
| 28 Jul 2023 | $4.74 | $-0.06 | -1.25% | 613,875 | $4.78 | $4.80 | $4.71 |
| 27 Jul 2023 | $4.80 | $0.10 | 2.13% | 869,928 | $4.72 | $4.81 | $4.68 |
| 26 Jul 2023 | $4.70 | $0.00 | 0.00% | 320,509 | $4.71 | $4.76 | $4.65 |
| 25 Jul 2023 | $4.70 | $-0.06 | -1.26% | 560,439 | $4.79 | $4.82 | $4.65 |
| 24 Jul 2023 | $4.76 | $-0.01 | -0.21% | 306,563 | $4.75 | $4.81 | $4.72 |
| 21 Jul 2023 | $4.77 | $-0.06 | -1.24% | 724,251 | $4.83 | $4.83 | $4.63 |
| 20 Jul 2023 | $4.83 | $0.01 | 0.21% | 393,430 | $4.85 | $4.93 | $4.81 |
| 19 Jul 2023 | $4.82 | $0.00 | 0.00% | 377,587 | $4.88 | $4.88 | $4.77 |
| 18 Jul 2023 | $4.82 | $-0.02 | -0.41% | 217,458 | $4.88 | $4.89 | $4.74 |
| 17 Jul 2023 | $4.84 | $0.09 | 1.89% | 365,567 | $4.79 | $4.87 | $4.71 |
| 14 Jul 2023 | $4.75 | $-0.01 | -0.21% | 629,577 | $4.79 | $4.79 | $4.63 |
| 13 Jul 2023 | $4.76 | $0.21 | 4.62% | 689,219 | $4.65 | $4.80 | $4.58 |
| 12 Jul 2023 | $4.55 | $-0.09 | -1.94% | 269,337 | $4.65 | $4.65 | $4.54 |
| 11 Jul 2023 | $4.64 | $0.08 | 1.75% | 507,251 | $4.62 | $4.64 | $4.55 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 08 Jun 2023 | Michael Kavanagh | Sell | 25 | $120,732 |
On-market trade.
|
| 08 Mar 2023 | David Fisher | Sell | 110 | $503,937 |
On-market trade.
|
| 19 Jan 2023 | Michael Kavanagh | Issued | 537 | $2,753,100 |
Issue of securities. 12,63,681 Rights
|
| 30 Sep 2022 | Michael Kavanagh | Expiry | 12 | $44,668 |
As advised by the company. lapsed , 7,25,966 rights
|
| 30 Sep 2022 | Michael Kavanagh | Expiry | 178 | $619,042 |
Options expired.
|
| 07 Sep 2022 | Lisa McIntyre | Buy | 5 | $19,994 |
On-market trade.
|
| 29 Aug 2022 | Michael Kavanagh | Issued | 59 | $244,743 |
Exercise of options.
|
| 29 Aug 2022 | Michael Kavanagh | Exercise | 158 | $654,522 |
Exercise of options.
|
| 25 Aug 2022 | Michael Kavanagh | Sell | 220 | $959,700 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Lisa Margaret McIntyre | Non-Executive Director | Dec 2019 |
Dr McIntyre joined the Nanosonics Board in November 2019. Her executive background is in strategy, particularly in the areas of medical technology and healthcare as a partner at L.E.K. Consulting in the US and Australia where she led the Asia Pacific Health practice. Dr. McIntyre was a Director of the Garvan Institute of Medical Research for 12 years.
|
| Mr David Fisher | Non-Executive Director | Jul 2001 |
Dr Fisher has been a member of the Board since July 2001. He is a founding partner of Brandon Capital Partners, a leading Australian venture capital provider. Dr Fisher has more than 35 years' operating experience in the biotechnology and healthcare industry in Australia and overseas. He held senior positions with Pharmacia AB (now part of Pfizer, Inc) and was CEO of Peptech Limited (now part of Cephalon Inc.
|
| Mr Michael Kavanagh | Chief Executive OfficerManaging Director | Jul 2012 |
Mr Kavanagh was a Non-executive Director of the Board from July 2012 to October 2013. Mr Kavanagh has more than 29 years of international commercial experience in the healthcare market, having held local, regional and global roles in medical device and pharmaceutical industries.
|
| Ms Marie Elizabeth McDonald | Non-Executive Director | Oct 2016 |
Ms McDonald joined the Nanosonics Board in October 2016, bringing with her a background in corporate and commercial law, having practiced as a partner at Ashurst. Ms McDonald was Chair of the Corporations Committee of the Business Law Section of the Law Council of Australia (2012 to 2013) and was a member of the Australian Takeovers Panel from 2001 to 2010.
|
| Mr Steven Andrew Sargent | Non-Executive DirectorNon-Executive Chairman | Jul 2016 |
Mr Sargent had a 22-year career with General Electric and has extensive global experience across a range of industries, including financial services and healthcare. He was Vice President and Officer of GE, a member of GE's Corporate Executive Council and CEO of GE Australia NZ. Mr Sargent is currently a Director of Origin Energy, Chairman of OFX Group, a Director of the Great Barrier Reef Foundation and Chairman of The Origin Foundation.
|
| Mr Geoff Raymond Wilson | Non-Executive Director | Jul 2019 |
Mr Wilson joined the Board in July 2019. He has a local and international executive leadership and director experience together spanning more than 37 years, including many years with KPMG in Australia, Hong Kong and the USA. Mr Wilson is currently a Director of TOLL Holdings Limited, HSBC Bank Australia Limited, Future Generation Global Investment Company Limited.
|
| Mr Matthew Carbines | General CounselCompany Secretary | May 2023 |
-
|
| Matthew Lipscombe | Chief Marketing Officer |
-
|
|
| Rod Lopez | Chief Operating Officer |
-
|
|
| Jodi Sampson | Chief People and Culture Officer |
-
|
|
| David Morris | Chief Strategy Officer and Regional President Asia Pacific |
-
|
|
| Steven Farrugia | Chief Technology Officer |
-
|
|
| Matthew Carbines | General Counsel |
-
|
|
| Matthew Carbines | General CounselCompany Secretary |
-
|
|
| Ronan Wright | Regional President for Europe and Middle East |
-
|
|
| Ken Shaw | Regional President for North America |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 67,537,345 | 22.37% |
| J P Morgan Nominees Australia Pty Limited | 41,848,804 | 13.86% |
| Citicorp Nominees Pty Limited | 32,323,481 | 10.71% |
| BNP Paribas Noms Pty Ltd <Drp> | 17,889,824 | 5.93% |
| Mr Bernard Stang | 9,389,048 | 3.11% |
| UBS Nominees Pty Ltd | 9,015,071 | 2.99% |
| Mr Maurie Stang | 8,629,534 | 2.86% |
| Mr Steve Kritzler | 7,489,737 | 2.48% |
| National Nominees Limited | 7,370,598 | 2.44% |
| Australian Foundation Investment Company Limited | 5,970,000 | 1.98% |
| Mirrabooka Investments Limited | 2,276,674 | 0.75% |
| Dr Harry Hirschowitz | 2,139,090 | 0.71% |
| HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> | 1,968,977 | 0.65% |
| Asia Union Investments Pty Limited | 1,700,000 | 0.56% |
| BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C> | 1,580,028 | 0.52% |
| Amcil Limited | 1,228,000 | 0.41% |
| Colonial First State Inv Ltd <2349414 Hofbauer A/C> | 1,200,000 | 0.40% |
| Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> | 1,130,050 | 0.37% |
| Powerwrap Limited <Escala Sma Trading A/C> | 1,039,457 | 0.34% |
| Mr Michael Kavanagh | 1,018,363 | 0.34% |